pirogovestnikВестник Национального медико-хирургического центра им. Н.И. ПироговаBulletin of Pirogov National Medical & Surgical Center2072-82552782-3628Национальный медико-хирургический Центр им. Н.И. Пирогова10.25881/20728255_2024_19_4_159pirogovestnik-245Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSПЕРВАЯ УСПЕШНАЯ ВЫСОКОДОЗНАЯ ХИМИОТЕРАПИЯ С АУТОЛОГИЧНОЙ ТРАНСПЛАНТАЦИЕЙ КРОВЕТВОРНЫХ СТВОЛОВЫХ КЛЕТОК ПРИ ЛИМФОМЕ ХОДЖКИНА У БОЛЬНОГО С ВИЧ-ИНФЕКЦИЕЙTHE FIRST SUCCESSFUL EXPERIENCE OF HIGH-DOSE CHEMOTHERAPY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA IN A PATIENT WITH HIV INFECTION AT THE PIROGOV NATIONAL MEDICAL AND SURGICAL CENTERМочкинН. Е.MochkinN. E.

Москва 

 Moscow 

nickmed@yandex.ruМельниченкоВ. Я.MelnichenkoV. Ya.

Москва

 Moscow 

ДеминаЕ. А.DeminaE. A.

Москва

 Moscow 

ПротопоповаЮ. В.ProtopopovaYu. V.

Москва

 Moscow 

ФГБУ «Национальный медико-хирургический Центр им. Н.И. Пирогова»РоссияPirogov National Medical and Surgical CenterRussian Federation202425122024194159164Copyright © Мочкин Н.Е., Мельниченко В.Я., Демина Е.А., Протопопова Ю.В., 20242024Мочкин Н.Е., Мельниченко В.Я., Демина Е.А., Протопопова Ю.В.Mochkin N.E., Melnichenko V.Y., Demina E.A., Protopopova Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://submit.pirogov-vestnik.ru/jour/article/view/245

Риск развития лимфомы Ходжкина (ЛХ) у ВИЧ-инфицированных пациентов в 5–26 раз выше по сравнению с общей популяции. У пациентов с ВИЧ ЛХ может развиваться даже при умеренном снижении иммунитета, несмотря на прием антиретровирусной терапии. В статье рассматривается современная тактика лечения ЛХ у ВИЧ-инфицированных пациентов, а также описывается первый успешный опыт проведения высокодозной химиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток (ВДХТ+аутоТГСК) у ВИЧ-инфицированного пациента в клинике гематологии ФГБУ «НМХЦ им Н. И. Пирогова». Наше клиническое наблюдение подтверждает эффективность и безопасность ВДХТ+аутоТГСК при лечении рецидивов и рефрактерных форму ЛХ у пациентов с ВИЧ-инфекцией.

The risk of developing Hodgkin Lymphoma (HL) is 5 to 26 times higher in HIV-infected patients compared to the general population. HL can develop even with moderate immune suppression and treatment with antiretroviral medicines. This article reviews the current treatment strategy for HL in HIV-infected patients and describes the first successful experience of high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) in an HIV-infected patient at the Hematology Department of the Pirogov National Medical and Surgical Center. This clinical case demonstrates the efficacy and safety of autoHSCT for treatment of relapsed and refractory HL in patients with HIV infection.

ВИЧ-инфекциялимфома Ходжкинааутологичная трансплантация гемопоэтических стволовых клетокHIV infectionHodgkin lymphomaautologous hematopoietic stem cell transplantationReferencesGopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. Moving Forward in HIVAssociated Cancer. JCO. 2014; 32(9): 876-880. doi: 10.1200/JCO.2013.53.1376.Gopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. Moving Forward in HIVAssociated Cancer. JCO. 2014; 32(9): 876-880. doi: 10.1200/JCO.2013.53.1376.Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS Associated Lymphoma: Review. BLCTT. 2022; 12: 31-45. doi: 10.2147/BLCTT.S361320.Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS Associated Lymphoma: Review. BLCTT. 2022; 12: 31-45. doi: 10.2147/BLCTT.S361320.Castro KG, Ward JW, Slutsker L, et al. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Published online 1993.Castro KG, Ward JW, Slutsker L, et al. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Published online 1993.Navarro JT, Moltó J, Tapia G, Ribera JM. Hodgkin Lymphoma in People Living with HIV. Cancers. 2021; 13(17): 4366. doi: 10.3390/cancers13174366.Navarro JT, Moltó J, Tapia G, Ribera JM. Hodgkin Lymphoma in People Living with HIV. Cancers. 2021; 13(17): 4366. doi: 10.3390/cancers13174366.Bachanova V, Connors JM. Hodgkin lymphoma in the elderly, pregnant, and HIV-infected. Seminars in Hematology. 2016; 53(3): 203-208. doi: 10.1053/j.seminhematol.2016.05.002.Bachanova V, Connors JM. Hodgkin lymphoma in the elderly, pregnant, and HIV-infected. Seminars in Hematology. 2016; 53(3): 203-208. doi: 10.1053/j.seminhematol.2016.05.002.Castillo JJ, Bower M, Brühlmann J, et al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. Cancer. 2015; 121(3): 423-431. doi: 10.1002/cncr.29066.Castillo JJ, Bower M, Brühlmann J, et al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. Cancer. 2015; 121(3): 423-431. doi: 10.1002/cncr.29066.Carbone A, Gloghini A, Caruso A, De Paoli P, Dolcetti R. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. International Journal of Cancer. 2017; 140(6): 1233-1245. doi: 10.1002/ijc.30473.Carbone A, Gloghini A, Caruso A, De Paoli P, Dolcetti R. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. International Journal of Cancer. 2017; 140(6): 1233-1245. doi: 10.1002/ijc.30473.Miller CL, Burkhardt AL, Lee JH, et al. Integral membrane protein 2 of Epstein—barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 1995; 2(2): 155-166. doi: 10.1016/S1074-7613(95)80040-9.Miller CL, Burkhardt AL, Lee JH, et al. Integral membrane protein 2 of Epstein—barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 1995; 2(2): 155-166. doi: 10.1016/S1074-7613(95)80040-9.Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals. Immunity. 1998; 9(3): 405-411. doi: 10.1016/S1074-7613(00)80623-8.Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals. Immunity. 1998; 9(3): 405-411. doi: 10.1016/S1074-7613(00)80623-8.Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008; 26(1): 677-704. doi: 10.1146/annurev.immunol.26.021607.090331.Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008; 26(1): 677-704. doi: 10.1146/annurev.immunol.26.021607.090331.Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720-1748. doi: 10.1038/s41375-022-01620-2.Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720-1748. doi: 10.1038/s41375-022-01620-2.Jacobson CA, Abramson JS. HIV-Associated Hodgkin’s Lymphoma: Prognosis and Therapy in the Era of cART. Advances in Hematology. 2012; 2012: 1-8. doi: 10.1155/2012/507257.Jacobson CA, Abramson JS. HIV-Associated Hodgkin’s Lymphoma: Prognosis and Therapy in the Era of cART. Advances in Hematology. 2012; 2012: 1-8. doi: 10.1155/2012/507257.Ruiz M, Parsons C, Cole J. Characterization of HIV-Associated Hodgkin’s Lymphoma in HIVInfected Patients: A Single-Center Experience. Journal of the International Association of Physicians in AIDS Care. 2012; 11(4): 234-238. doi: 10.1177/1545109711431492.Ruiz M, Parsons C, Cole J. Characterization of HIV-Associated Hodgkin’s Lymphoma in HIVInfected Patients: A Single-Center Experience. Journal of the International Association of Physicians in AIDS Care. 2012; 11(4): 234-238. doi: 10.1177/1545109711431492.Olszewski AJ, Castillo JJ. Outcomes of HIVassociated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016; 30(5): 787-796. doi: 10.1097/QAD.0000000000000986.Olszewski AJ, Castillo JJ. Outcomes of HIVassociated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016; 30(5): 787-796. doi: 10.1097/QAD.0000000000000986.Hentrich M, Müller M, Wyen C, et al. Stageadapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study. HemaSphere. 2024; 8(7): e68. doi: 10.1002/hem3.68.Hentrich M, Müller M, Wyen C, et al. Stageadapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study. HemaSphere. 2024; 8(7): e68. doi: 10.1002/hem3.68.Souza AT de, Andrade FR de, Sarmento AC, Villarim CC, Araújo-Filho I, Medeiros KS de. Clinical features in Hodgkin lymphoma patients living with human immunodeficiency virus: A metaanalysis in the antiretroviral therapy era. Int J STD AIDS. Published online June 21, 2024: 0956462-4241259512. doi: 10.1177/09564624241259512.Souza AT de, Andrade FR de, Sarmento AC, Villarim CC, Araújo-Filho I, Medeiros KS de. Clinical features in Hodgkin lymphoma patients living with human immunodeficiency virus: A metaanalysis in the antiretroviral therapy era. Int J STD AIDS. Published online June 21, 2024: 0956462-4241259512. doi: 10.1177/09564624241259512.Chekalov A, Popova M, Tsygankov I, et al. P10-77: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETROSPECTIVE MULTICENTER STUDY. HemaSphere. 2022; 6: 67-968. doi: 10.1097/01.HS9.0000847176.96022.91.Chekalov A, Popova M, Tsygankov I, et al. P10-77: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETROSPECTIVE MULTICENTER STUDY. HemaSphere. 2022; 6: 67-968. doi: 10.1097/01.HS9.0000847176.96022.91.Berenguer J, Miralles P, Ribera JM, et al. Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2008; 47(4). https://journals.lww.com/jaids/fulltext/2008/04010/characteristics_and_outcome_of_aids_related.3.aspx.Berenguer J, Miralles P, Ribera JM, et al. Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2008; 47(4). https://journals.lww.com/jaids/fulltext/2008/04010/characteristics_and_outcome_of_aids_related.3.aspx.Montoto S, Shaw K, Okosun J, et al. HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. JCO. 2012; 30(33): 4111-4116. doi: 10.1200/JCO.2011.41.4193.Montoto S, Shaw K, Okosun J, et al. HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. JCO. 2012; 30(33): 4111-4116. doi: 10.1200/JCO.2011.41.4193.Besson C, Lancar R, Prevot S, et al. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. Clinical Infectious Diseases. 2015; 61(9): 1469-1475. doi: 10.1093/cid/civ627.Besson C, Lancar R, Prevot S, et al. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. Clinical Infectious Diseases. 2015; 61(9): 1469-1475. doi: 10.1093/cid/civ627.Sorigué M, García O, Tapia G, et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. AIDS. 2017; 31(10): 1445-1449. doi: 10.1097/QAD.0000000000001487.Sorigué M, García O, Tapia G, et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. AIDS. 2017; 31(10): 1445-1449. doi: 10.1097/QAD.0000000000001487.Lawal IO, Ankrah AO, Popoola GO, et al. 18FFDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma. Nuclear Medicine Communications. 2018; 39(11): 1005-1012. doi: 10.1097/MNM.0000000000000905.Lawal IO, Ankrah AO, Popoola GO, et al. 18FFDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma. Nuclear Medicine Communications. 2018; 39(11): 1005-1012. doi: 10.1097/MNM.0000000000000905.Danilov AV, Li H, Press OW, et al. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leukemia & Lymphoma. 2017; 58(2): 461-465. doi: 10.1080/10428194.2016.1201573.Danilov AV, Li H, Press OW, et al. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leukemia & Lymphoma. 2017; 58(2): 461-465. doi: 10.1080/10428194.2016.1201573.Blanca X, Josep-María R, Pilar M, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. haematol. 2007; 92(2): 191-198. doi: 10.3324/haematol.10479.Blanca X, Josep-María R, Pilar M, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. haematol. 2007; 92(2): 191-198. doi: 10.3324/haematol.10479.Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Annals of Oncology. 2003;14(10):1562-1569. doi:10.1093/annonc/mdg408.Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Annals of Oncology. 2003;14(10):1562-1569. doi:10.1093/annonc/mdg408.Hentrich M, Berger M, Wyen C, et al. Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. JCO. 2012; 30(33): 4117-4123. doi: 10.1200/JCO.2012.41.8137.Hentrich M, Berger M, Wyen C, et al. StageAdapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. JCO. 2012; 30(33): 4117-4123. doi: 10.1200/JCO.2012.41.8137.Rubinstein PG, Moore PC, Bimali M, et al. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet Haematology. 2023; 10(8): e624-e632. doi: 10.1016/S2352-3026(23)00157-6.Rubinstein PG, Moore PC, Bimali M, et al. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet Haematology. 2023; 10(8): e624-e632. doi: 10.1016/S2352-3026(23)00157-6.Mponda M, Kudowa E, Craven DM, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. eClinicalMedicine. 2024; 69: 10-2480. doi: 10.1016/j.eclinm.2024.102480.Mponda M, Kudowa E, Craven DM, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. eClinicalMedicine. 2024; 69: 10-2480. doi: 10.1016/j.eclinm.2024.102480.Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from pivotal phase 2 CheckMate 205 study. Blood Advances. Published online August 2, 2023: bloodadvances.2023010334. doi: 10.1182/bloodadvances.2023010334.Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from pivotal phase 2 CheckMate 205 study. Blood Advances. Published online August 2, 2023: bloodadvances.2023010334. doi: 10.1182/bloodadvances.2023010334.Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023; 142(10): 878-886. doi: 10.1182/blood.2022019386.Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023; 142(10): 878-886. doi: 10.1182/blood.2022019386.Mei MG, Lee HJ, Palmer JM, et al. Responseadapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25): 3605-3616. doi: 10.1182/blood.2022015423.Mei MG, Lee HJ, Palmer JM, et al. Responseadapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25): 3605-3616. doi: 10.1182/blood.2022015423.Pier LZ, Simonetta V, Antonella A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. haematol. 2013; 98(8): 1232-1236. doi: 10.3324/haematol.2012.083048.Pier LZ, Simonetta V, Antonella A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. haematol. 2013; 98(8): 1232-1236. doi: 10.3324/haematol.2012.083048.Lurain K, Zarif TE, Ramaswami R, et al. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical Lymphoma, Myeloma and Leukemia. 2024; 24(8): 523-530. doi: 10.1016/j.clml.2024.03.011.Lurain K, Zarif TE, Ramaswami R, et al. RealWorld Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical Lymphoma, Myeloma and Leukemia. 2024; 24(8): 523-530. doi: 10.1016/j.clml.2024.03.011.Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23): 4934-4937. doi: 10.1182/blood-2010-05-282756.Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23): 4934-4937. doi: 10.1182/blood-2010-05-282756.Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005; 105(2): 874-878. doi: 10.1182/blood-2004-04-1532.Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005; 105(2): 874-878. doi: 10.1182/blood-2004-04-1532.Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009; 114(7): 1306-1313. doi: 10.1182/blood-2009-02-202762.Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009; 114(7): 1306-1313. doi: 10.1182/blood-2009-02-202762.National Comprehensive Cancer Network. Cancer in People with HIV (Version: 2.2024). April 4, 2024. https://www.nccn.org/professionals/physician_gls/pdf/hiv.pdf.National Comprehensive Cancer Network. Cancer in People with HIV (Version: 2.2024). April 4, 2024. https://www.nccn.org/professionals/physician_gls/pdf/hiv.pdf.Bae S, Kim YJ, Kim M ju, et al. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J Immunother Cancer. 2021;.9(9):. e002960. doi:.10.1136/jitc-2021-002960.Bae S, Kim YJ, Kim M ju, et al. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J Immunother Cancer. 2021;.9(9):. e002960. doi:.10.1136/jitc-2021-002960.

The authors declare that there are no conflicts of interest present.